Literature DB >> 11792589

Polymorphism in the type I collagen (COLIA1) gene and risk of fractures in postmenopausal women.

M Bernad1, M E Martinez, M Escalona, M L González, C González, M V Garcés, M T Del Campo, E Martín Mola, R Maderò, L Carreñò.   

Abstract

Twin and family studies have demonstrated that a large part of a population's variance in bone mineral density (BMD) is attributable to genetic factors. A polymorphism in the collagen type I alpha1 (COLIA1) gene has recently been associated with low bone mass and fracture incidence. We analyzed the relationship between COLIA1 gene polymorphism, lumbar spine and hip BMD, and fracture prevalence in a population of 319 postmenopausal women classified by WHO standards, including 98 nonosteoporotic women (NOPW) and 221 osteoporotic postmenopausal women (OPW), divided into 139 osteoporotic women without fracture (OPWnF) and 82 osteoporotic women with fracture (OPWwF). The COLIA1 genotype was assessed by polymerase chain reaction and BalI endonuclease digestion. Genotype frequencies for the total group were 49.2% GG homozygotes, 39.5% GT heterozygotes, and 11.3% TT homozygotes. We found significant differences in the percentage of homozygous TT between NOPW and OPW (6.1% and 13.6%, respectively). Significantly, the occurrence of genotype TT in OPWnF was 6.2%, and 28% in OPWwF. We observed no associations between the COLIA1 genotype and lumbar spine and hip BMD. The prevalence of fractures varied significantly by genotype: GG, 26.1%; GT, 15.9%; and TT, 58.3%. Logistic regression analysis of fracture prevalence showed that, for prevalent fractures, the women with the TT genotype had a 5.9-fold increased risk when compared with the other genotypes (GG + GT). When prevalence was adjusted for age, body mass index, and BMD, the fracture risk was 4.8 for the TT group vs. the genotype GG, whereas it was 0.6 for the GT genotype. In conclusion, we found the COLIA1 Sp1 TT genotype to be associated with an increased fracture risk in postmenopausal women. Interestingly, this genotype-dependent risk could not be explained completely by BMD differences.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792589     DOI: 10.1016/s8756-3282(01)00639-1

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

1.  Association of estrogen receptor alpha and collagen type I alpha 1 gene polymorphisms with bone mineral density in postmenopausal women.

Authors:  M O Erdogan; H Yıldız; S Artan; M Solak; F Taşcıoğlu; U Dündar; B Eser; E Colak
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  Polymorphisms in the 5' flank of COL1A1 gene and osteoporosis: meta-analysis of published studies.

Authors:  H Jin; E Evangelou; J P A Ioannidis; S H Ralston
Journal:  Osteoporos Int       Date:  2010-08-27       Impact factor: 4.507

3.  Genetic polymorphisms of collagen type I α1 chain (COL1A1) gene increase the frequency of low bone mineral density in the subgroup of children with juvenile idiopathic arthritis.

Authors:  Arseniy M Smirnov; Grigory S Demin; Marina M Mnuskina; Larisa A Scheplyagina; Mikhail M Kostik; Valentina I Larionova
Journal:  EPMA J       Date:  2013-06-13       Impact factor: 6.543

Review 4.  Searching for genes underlying susceptibility to osteoporotic fracture: current progress and future prospect.

Authors:  S-F Lei; H Jiang; F-Y Deng; H-W Deng
Journal:  Osteoporos Int       Date:  2007-05-30       Impact factor: 4.507

5.  COL1A1 Sp1-binding site polymorphism as a risk factor for genital prolapse.

Authors:  Andrea Moura Rodrigues; Manoel João Batista Castello Girão; Ismael Dale Cotrim Guerreiro da Silva; Marair Gracio Ferreira Sartori; Karina de Falco Martins; Rodrigo de Aquino Castro
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06-13

6.  Association analysis of the COL1A1 polymorphism with bone mineral density and prevalent fractures in Polish postmenopausal women with osteoporosis.

Authors:  Joanna Dytfeld; Michalina Marcinkowska; Natalia Drwęska-Matelska; Michał Michalak; Wanda Horst-Sikorska; Ryszard Słomski
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.